1기리쉬를 xbet., Ltd.

• If approved by the European Commission, Abilify Ma1기리쉬를 xbettena^™would become the only dopamine D2 partial agonist in once-monthly, injectable 1기리쉬를 xbetm 1기리쉬를 xbet maintenance treatment of schizophrenia in adult patients stabilized with oral aripiprazole.
• Reduc1기리쉬를 xbetg the risk of relapse is an important consideration 1기리쉬를 xbet the treatment of patients with schizophrenia. Cl1기리쉬를 xbetical trials demonstrated that Abilify Ma1기리쉬를 xbettena reduced the risk of relapse 1기리쉬를 xbet adult patients with schizophrenia 1기리쉬를 xbet comparison with placebo.
• Approval of this new once-monthly 1기리쉬를 xbetmulation of aripiprazole in Europe will provide patients with schizophrenia with an effective and well-tolerated alternative treatment option.

(Tokyo, Japan and Copenhagen, Denmark, 20 September, 2013) - 1기리쉬를 xbet., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorization for Abilify Maintena (aripiprazole), an intramuscular (IM) depot formulation indicated for maintenance treatment of schizophrenia in adult patients stabilized with oral aripiprazole.